<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05093153</url>
  </required_header>
  <id_info>
    <org_study_id>PRAME</org_study_id>
    <nct_id>NCT05093153</nct_id>
  </id_info>
  <brief_title>Spanish Registry of Patients With IgM Monoclonal Gammopathies</brief_title>
  <acronym>PRAME</acronym>
  <official_title>Spanish Registry of Patients With Diagnosis of IgM-MGUS, Asymptomatic &amp; Symptomatic Waldenström Macroglobulinemia. Analysis of Clinical and Laboratory Features, Treatment and Outcomes.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Española de Hematología y Hemoterapía</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación Española de Hematología y Hemoterapía</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Waldenström's macroglobulinemia (WM) is a B-cell lymphoproliferative disorder which is&#xD;
      defined by bone marrow infiltration by small lymphocytes, lymphoplasmacytoid and plasma cells&#xD;
      together with the presence of a detectable monoclonal immunoglobulin M (IgM).The clinical&#xD;
      presentation of WM is variable. Symptoms can be related to tumor infiltration, or they can be&#xD;
      related to the monoclonal IgM component. The therapeutic options are heterogeneous and there&#xD;
      are no well-established in both first line or relapse/refractory settings. In Spain, the&#xD;
      incidence of MGUS-IgM and WM in the last decade is unknown.&#xD;
&#xD;
      The aims of this retrospective, observational, multicentric study is:&#xD;
&#xD;
        -  To develop a national registry of patients diagnosed with Waldenström's&#xD;
           Macroglobulinemia and Monoclonal Gammopathy of uncertain significance -IgM in Spain in&#xD;
           the past 30years.&#xD;
&#xD;
        -  To evaluate the most relevant clinical characteristics, long-term safety and efficacy of&#xD;
           different therapeutic schemes and long-term prognosis of patients with WM&#xD;
&#xD;
        -  To help in the design of future therapeutic strategies, risk prognostic factors and&#xD;
           clinical trials in Spain.&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      The investigators will collect data from the patient clinical files after prior Informed&#xD;
      Consent providing from patients with diagnosis of MGUS-IgM and WM in the past 30 years in&#xD;
      Spain, according to the WHO classification of lymphoid tumors (2008) revised in 2016. Data&#xD;
      from patients not able to provide IC (i.e., already dead patients) will be included only&#xD;
      after the permission of the ethics review board.&#xD;
&#xD;
      The collected data will be included in a database of the Spanish Myeloma and Lymphoma&#xD;
      Intergroup (SMALI) team created ad-hoc by the Spanish Society of Hematology and Hemotherapy&#xD;
      (SEHH). Each principal investigator in each center will conduct their technical supervision.&#xD;
      The evaluation of the treatment protocols will be done following the indications of the&#xD;
      intergroup committee according to the guidelines of the International Waldenström's&#xD;
      Macroglobulinemia Group.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>through study completion, an average of 4 years</time_frame>
    <description>Overall survival evaluation from the date of diagnosis to the death of the patient due to any cause</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Waldenstrom Macroglobulinemia</condition>
  <arm_group>
    <arm_group_label>Waldenström's macroglobulinemia cohort patient</arm_group_label>
    <description>Adult patients diagnosed with Waldenström's Macroglobulinemia</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with Waldenström's Macroglobulinemia and Monoclonal Gammopathy of&#xD;
        uncertain significance&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  Patients having a confirmed diagnosis of either in the las 30 years:&#xD;
&#xD;
          -  Monoclonal Gammopathy of uncertain significance -IgM&#xD;
&#xD;
          -  Asymptomatic Waldenström's macroglobulinemia&#xD;
&#xD;
          -  Symptomatic Waldenström's macroglobulinemia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other subtypes of Lymphoproliferative diseases.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>RAMON GARCIA SANZ, MD</last_name>
    <phone>+34 923 291100</phone>
    <phone_ext>56606</phone_ext>
    <email>rgarcias@usal.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>ELHAM ASKARI ASKARI, MD</last_name>
    <phone>+34 91 5504800</phone>
    <phone_ext>2433</phone_ext>
    <email>easkari@fdj.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Marques de Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arancha Bermúdez, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 28, 2021</study_first_submitted>
  <study_first_submitted_qc>October 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2021</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

